Veraxa Biotech becomes a publicly traded company
Swiss company Veraxa Biotech has announced that it will list on the Nasdaq stock exchange via a SPAC. The company has entered into a US$1.6 billion deal with a SPAC firm. The merger with Voyager Acquisition will bring Veraxa’s valuation to approximately US$1.3 billion. This figure does not include the trust fund analysis. The value of the combined company is US$1.6 billion. This was achieved by keeping the share price at US$10 per unit.
The deal is due to close in Q4 of 2025. Subsequently, Veraxa will receive US$253 million in gross proceeds. These will be deposited into SPAC Voyager’s trust account.
Founded in Zurich in 2020, Veraxa specialises in the development of innovative antibody conjugates and drugs for the treatment of cancer. It specialises in developing innovative antibody conjugates and drugs for treating cancer. The company has introduced several products, some of which have already passed clinical trials. Some projects are at an early stage of development. The company also has research units in Germany.
Sector trends
The biotechnology market has grown considerably in recent years. There has been an increase in mergers and acquisitions, as well as investment in various industry segments. For example, drug developers specialising in cancer treatment are in high demand. The following data supports this:
1. Analysts valued the global oncology sector at over US$320 billion in 2024.
2. They expect it to reach US$345 billion by the end of 2025.
3. The valuation of the sector by 2034 will be more than US$866 billion.
There are a number of reasons why the designated segment is promising. One key reason is that cancer continues to spread globally. At the same time, the number of diagnostic laboratories in developed countries is growing. In turn, governments and private companies continue to invest in the research and development of new treatment methods. Investment in modernising healthcare infrastructure to improve early diagnosis is also growing.
The impact of AI
The development of advanced technologies is fuelling demand for biotechnology. Artificial intelligence and other digital innovations are significantly accelerating the development of new treatments. They are also helping to introduce personalised and telemedicine services, as well as making CAR-T cell therapy available. CAR-T cell therapy is considered a cutting-edge cancer treatment and could represent a breakthrough in the field.
Government support, technological innovation and growing demand are fuelling the emergence of new biotech companies. Many of these companies are acquiring major competitors to consolidate their long-term market position.
